Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
Crossref DOI link: https://doi.org/10.1007/s13365-016-0449-0
Published Online: 2016-05-19
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Werner, Milton H.
Huang, DeRen
Funding for this research was provided by:
Inhibikase Therapeutics, Inc.
License valid from 2016-05-19